Hooi Lai Seong, Lim Teck Onn, Goh Adrian, Wong Hin Seng, Tan Chwee Choon, Ahmad Ghazali, Morad Zaki
Haemodialysis Unit, Sultanah Aminah Hospital, Johor Bahru 80100, Malaysia.
Nephrology (Carlton). 2005 Feb;10(1):25-32. doi: 10.1111/j.1440-1797.2005.00360.x.
This is a multi-centre study to determine cost efficiency and cost effectiveness of the Ministry of Health centre haemodialysis and continuous ambulatory peritoneal dialysis (CAPD) programme.
Forty-four haemodialysis and 11 CAPD centres were enrolled in this study in 2001. Sixty patients, 30 from each modality, were evaluated. Micro-costing was used to determine costs.
The number of haemodialyses conducted ranged from 402 to 23,000 procedures per year, while for CAPD, output ranged from 70 to 2300 patient months/year. Cost ranged from RM79.61 to RM475.79 per haemodialysis treatment, with a mean cost of RM169 per HD (USD 1 = RM 3.80). The cost of CAPD treatment ranged from RM1400 to RM3200 per patient month, with a mean of RM2186. Both modalities incurred similar outpatient costs. The cost of erythropoeitin per year is RM4500 and RM2500 for haemodialysis and CAPD, respectively. The number of life years saved is 10.96 years for haemodialysis and 5.21 years for CAPD. Cost per life year saved is RM33 642 for haemodialysis and RM31 635 for CAPD. The cost for land, building, equipment, overheads, and staff were higher for haemodialysis, while consumables and hospitalization cost more for CAPD. Sensitivity analysis was performed for two discount rates (3 and 5%), varying erythropoietin doses and maximum and minimum overheads. Relative cost effectiveness of haemodialysis and CAPD was unchanged in all sensitivity scenarios, except for overhead costs, which influenced the cost effectiveness of HD.
It is economically viable to promote the use of both CAPD and haemodialysis because the cost effectiveness of both are nearly equal.
这是一项多中心研究,旨在确定卫生部中心血液透析和持续性非卧床腹膜透析(CAPD)项目的成本效率和成本效益。
2001年,44个血液透析中心和11个CAPD中心参与了本研究。对60名患者进行了评估,每种透析方式各30名。采用微观成本核算来确定成本。
每年进行的血液透析次数在402至23000次之间,而CAPD的产出为每年70至2300患者月。每次血液透析治疗的成本在79.61令吉至475.79令吉之间,血液透析的平均成本为每例169令吉(1美元=3.80令吉)。CAPD治疗的成本为每名患者每月1400令吉至3200令吉,平均为2186令吉。两种透析方式的门诊成本相似。血液透析和CAPD每年的促红细胞生成素成本分别为4500令吉和2500令吉。血液透析挽救的生命年数为10.96年,CAPD为5.21年。血液透析每挽救一年生命的成本为33642令吉,CAPD为31635令吉。血液透析在土地、建筑、设备、间接费用和人员方面的成本较高,而CAPD的耗材和住院成本较高。对两种贴现率(3%和5%)、不同促红细胞生成素剂量以及最高和最低间接费用进行了敏感性分析。除间接费用影响血液透析的成本效益外,在所有敏感性情景下,血液透析和CAPD的相对成本效益均未改变。
推广使用CAPD和血液透析在经济上是可行的,因为两者的成本效益几乎相等。